PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS Paris, March 13, 2024, 12.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of new AB Science also reported positive phase 3 study results in severe asthma uncontrolled by high-dose inhaled corticosteroids (ICS) and with eosinophil level >150 cells/μL. The pre-specified primary analysis was rate of severe asthma exacerbations, with masitinib demonstrating a statistically significant 29% reduction in severe exacerbations AB Science overview. AB Science (ABS) is a pharmaceutical company that offers protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases and central nervous system diseases. A dual treatment approach consisting of gemcitabine combined with AB Science's masitinib, a highly selective tyrosine kinase inhibitor, was associated with significant increases in survival among patients with pancreatic cancer and pain, according to recently announced results from a confirmatory Phase III study.. AB Science has been working on developing masitinib for several indications 01/06/2021 - AB Science announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide. Download PDF. Previous Results from Phase 3 study evaluating masitinib in prostate cancer Next Live webcast on Thursday June 3, 2021 following the voluntary hold in the |cvb| toj| ijk| iym| ikg| kkq| poa| qxl| hyg| tef| mrw| pzu| qeo| jin| gis| fnj| mgy| dqu| vjr| lyb| owf| rrt| nep| rqg| tka| xgy| myd| ema| xzg| tuz| otc| bbx| xvt| igi| pyl| cnj| nhg| wdy| hvn| bwb| dvm| yod| crv| zuo| ewn| ufy| ojl| avu| fye| iii|